TPST Should I Buy

Tempest Therapeutics announced that the company plans to explore a full range of strategic alternatives to advance its clinical stage programs. Strategic alternatives under consideration may include, but are not limited to, mergers, acquisition, partnerships, joint ventures, licensing arrangements or other strategic transactions. The company has retained MTS Health Partners, a financial advisor with experience in the biotechnology industry, to support it with the strategic evaluation process. "Notwithstanding the positive randomized data set from the amezalpat Phase 2 and its blockbuster potential in first-line HCC, as well as the potential of TPST-1495 as it moves towards a Phase 2 in FAP, the capital markets have been unavailable to support the next stage of advancement," said Stephen Brady, president and chief executive officer of Tempest. "We are initiating a process to explore alternatives available to the company to maximize stockholder value, which include finding a strategic partner with the resources to develop what we believe are potentially life-saving therapies for patients in need. Given the positive data and commercial potential with this pipeline, as well as the clearance from FDA on the lead program's pivotal study, we believe this is a rare opportunity for a partner."